Merck & Co. Inc recalls Belsomra (suvorexant) tablets
- Published
- 20 Aug 2025
- Units affected
- 51,320 cartons
- Agency
- FDA
- Country
- United States
The hazard
Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)
- Brand / company
- Merck & Co. Inc
- Codes / lots
- Lots 2090019 and 2123744, Exp. 4/30/2027
- Distribution
- Nationwide in the USA and PR.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 20 Aug 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.